1-Methoxy-benzotriazol | 22713-34-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并三唑类
• 英文名称: 1-Methoxy-benzotriazol
• 英文别名: 1-Methoxybenzotriazole
• CAS: 22713-34-4
• 化学式: C₇H₇N₃O
• 分子量: 149.152
• InChiKey: ZHPSBMQVLQEIIC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  39.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-Methoxy-benzotriazol 在 sodium thiophenolate 作用下， 以 氘代二甲亚砜 、 氘代氯仿 为溶剂， 生成 1-羟基苯并三唑
  参考文献：
  名称：

  Comparison of the Effects of 5- and 6-HOAt on Model Peptide Coupling Reactions Relative to the Cases for the 4- and 7-Isomers^,

  摘要：

  [GRAPHICS]Synthesis of 5- and 6-HOAt has completed the full set of the four HOAt isomers derived from HOBt by insertion of a single nitrogen atom in the benzenoid nucleus. Comparison of the reactivity of all four isomers in model peptide coupling reactions has confirmed the unique character of the 7-isomer in promoting selectivity and maintaining configuration at the reactive carboxylic acid residue.

  DOI：

  10.1021/ol006013z
• 作为产物：
  描述：

  1-(甲氧基羰基)-1H-苯并d1,2,3噻唑3-氧化物 在 1-羟基苯并三唑 、 三乙胺 作用下， 以 吡啶 为溶剂， 生成 1-Methoxy-benzotriazol
  参考文献：
  名称：

  New Process for the Preparation of Methyl Carbonates

  摘要：

  graphicThe methyl carbonate of HOBt was developed for the conversion of alcohols to carbonates. This method is superior to the use of methyl chloroformate or methyl pyrocarbonate, especially with more hindered alcohols. The reagent is a stable solid that is easily prepared on a multigram scale.

  DOI：

  10.1021/ol034274d

文献信息

• COMPOUND HAVING READ-THROUGH ACTIVITY
  申请人：THE UNIVERSITY OF TOKYO

  公开号：US20140364642A1

  公开（公告）日：2014-12-11

  [Problem] Provision of a novel compound having read-through activity and a drug for the treatment of nonsense mutation-type disease containing this compound. [Solution] A compound represented by the following general formula (1): and a pharmaceutical composition containing this compound.

  一种具有读穿活性的新化合物以及包含该化合物的用于治疗无义突变型疾病的药物。 一种由以下一般式（1）表示的化合物： 以及含有该化合物的药物组合物。
• [EN] NOVEL CRYPTOPHYCIN COMPOUNDS AND CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE<br/>[FR] NOUVEAUX COMPOSÉS ET CONJUGUÉS DE CRYPTOPHYCINE, LEUR PRÉPARATION ET LEUR UTILISATION THÉRAPEUTIQUE
  申请人：SANOFI SA

  公开号：WO2017076998A1

  公开（公告）日：2017-05-11

  The present invention relates to cryptophycin compounds of formula (I). The invention also relates to cryptophycin payloads, to cryptophycin conjugates, to compositions containing them and to their therapeutic use, especially as anticancer agents. The invention also relates to the process for preparing these conjugates.

  本发明涉及公式（I）的隐藻素化合物。该发明还涉及隐藻素有效载荷、隐藻素偶联物、含有它们的组合物及其治疗用途，尤其是作为抗癌剂。该发明还涉及制备这些偶联物的过程。
• In Vivo Polynucleotide Delivery Conjugates Having Enzyme Sensitive Linkages
  申请人：Rozema David B.

  公开号：US20120172412A1

  公开（公告）日：2012-07-05

  The present invention is directed compositions for delivery of RNA interference (RNAi) polynucleotides to cells in vivo. The compositions comprise amphipathic membrane active polyamines reversibly modified with enzyme cleavable dipeptide-amidobenzyl-carbonate masking agents. Modification masks membrane activity of the polymer while reversibility provides physiological responsiveness. The reversibly modified polyamines (dynamic polyconjugate or DPC) are further covalently linked to an RNAi polynucleotide or co-administered with a targeted RNAi polynucleotide-targeting molecule conjugate.

  本发明涉及用于将RNA干扰（RNAi）多核苷酸传递至体内细胞的组合物。这些组合物包括与酶可切割二肽-酰胺基苄-碳酸酯掩蔽剂可逆修饰的两性膜活性多胺。修饰掩蔽了聚合物的膜活性，而可逆性提供了生理响应性。可逆修饰的多胺（动态多共轭物或DPC）进一步与RNAi多核苷酸共价连接，或与靶向RNAi多核苷酸的分子结合物共同给药。
• Facile synthesis of 1-alkoxy-1<i>H</i>-benzo- and 7-azabenzotriazoles from peptide coupling agents, mechanistic studies, and synthetic applications
  作者：Mahesh K Lakshman、Manish K Singh、Mukesh Kumar、Raghu Ram Chamala、Vijayender R Yedulla、Domenick Wagner、Evan Leung、Lijia Yang、Asha Matin、Sadia Ahmad

  DOI：10.3762/bjoc.10.200

  日期：——

  utility, this novel reaction has been used to prepare a series of acyclic nucleoside-like compounds. Because BtO(-) is a nucleofuge, several Bt-OCH2Ar substrates have been evaluated in nucleophilic substitution reactions. Finally, the possible formation of Pd pi-allyl complexes by departure of BtO(-) has been queried. Thus, alpha-allylation of three cyclic ketones was evaluated with 1-(cinnamyloxy)-1H-benzo[d][1

  (1H-苯并[d][1,2,3]三唑-1-基氧基)三(二甲氨基)鏻六氟磷酸盐(BOP)，1H-苯并[d][1,2,3]三唑-1-基4-甲基苯磺酸盐 (Bt-OTs) 和 3H-[1,2,3]三唑并[4,5-b]吡啶-3-基 4-甲基苯磺酸盐 (At-OTs) 通常用于肽合成中形成酰胺键。然而，这些化合物与醇在碱存在下发生先前未描述的反应，产生1-烷氧基-1H-苯并-(Bt-OR)和7-氮杂苯并三唑(At-OR)。尽管 BOP 与醇反应生成 1-烷氧基-1H-苯并三唑，但 Bt-OT 被证明更优越。伯醇和仲醇都在通常温和的反应条件下进行反应。相应地，由At-OTs合成了1-烷氧基-1H-7-氮杂苯并三唑。从机理上讲，这些肽偶联剂可通过三种途径与醇发生反应。从(31)P(1)H}、[(18)O]-标记和其他化学实验来看，醇的鏻和甲苯磺酸衍生物似乎是中间体。然后它们与原位产生的 BtO(-) 和
• [EN] A METHOD FOR MODIFICATION OF PEPTIDES IMMOBILIZED ON A SOLID SUPPORT BY TRACELESS REDUCTIVELY CLEAVABLE LINKER MOLECULES<br/>[FR] PROCÉDÉ DE MODIFICATION DE PEPTIDES IMMOBILISÉS SUR UN SUPPORT SOLIDE PAR DES MOLÉCULES DE LIAISON POUVANT ÊTRE CLIVÉES PAR RÉDUCTION SANS TRACE
  申请人：BELYNTIC GMBH

  公开号：WO2021023892A1

  公开（公告）日：2021-02-11

  The present invention relates to a method for modifying and purifying peptides comprising an immobilizing step, a modification step and a releasing step. In the immobilizing step, a crude linker-tagged peptide L-P is coupled to a solid support yielding an immobilized linker-tagged peptide S-L-P. Subsequently, the immobilized linker-tagged peptide S-L-P is modified with one or more organic molecules yielding an immobilized linker-tagged peptide S-L-mP. Finally, the modified peptide is released via a reduced intermediate RI. The linker molecule is a compound of formula 1, X-Tb-Va-U-Y-Z (1), which can be coupled to a purification resin via the moiety X and to a peptide via the moiety Y under the release of the leaving group Z. T is an optional spacer moiety and V is an optional electron withdrawing moiety. U is an aryl or 5- or 6-membered heteroaryl moiety bound to at least one electron withdrawing moiety V, W or E. The linker is stable under acidic conditions and releases the peptide upon addition of a reducing agent.

  本发明涉及一种修饰和纯化肽的方法，包括固定步骤、修饰步骤和释放步骤。在固定步骤中，将粗链联标记的肽L-P偶联到固体支持上，得到固定的链联标记的肽S-L-P。随后，用一个或多个有机分子修饰固定的链联标记的肽S-L-P，得到固定的链联标记的肽S-L-mP。最后，通过还原中间体RI释放修饰的肽。链联分子是化合物1的化学式，X-Tb-Va-U-Y-Z（1），可以通过基团X偶联到纯化树脂，通过基团Y偶联到肽，释放离去基团Z。T是可选的间隔基团，V是可选的电子吸引基团。U是芳基或与至少一个电子吸引基团V、W或E结合的芳基或5-或6-成员杂芳基基团。该链联在酸性条件下稳定，并在加入还原剂后释放肽。

表征谱图